In a fast-paced industry with big budget competition, you need every tool and approach to succeed.

This is the first installment in our 4-part Biotech Webinar Series. In this series, our experts will walk you through the development stages of an obesity drug, showcasing how AI-powered tools and modeling & simulation software can shorten the development timeline while increasing confidence in a compound’s efficacy and safety. They’ll demonstrate how to address common challenges with obesity (and other) drugs, such as identifying optimal dosing paradigms and minimizing gastrointestinal adverse events.

You’ll learn how AI-powered tools and modeling & simulation can help you…

• Accelerate the design & optimization of your drug candidates while prioritizing them based on potential hazards like DILI risk
• Determine the right dosing paradigms in as few iterations as possible
• Set up a clinical development plan to increase likelihood of acquisition and/or out-licensing
• Optimize your clinical trial protocol and training
• And more

At the end of each session, our experts will host a Q&A and answer your questions in real-time.

In this session, Drs. Jeremy Jones and Scott Q. Siler will introduce some of the common challenges in developing drugs targeting obesity. They will then dive into how AI-driven design and mechanistic modeling can shorten the discovery timeline while increasing confidence in the drug candidates selected for development.

Presenters:

• Scott Q. Siler – Chief Science Officer, Quantitative Systems Pharmacology
• Jeremy Jones – Principal Scientist, AIDD Applications, Cheminformatics Solutions